Delivery Order SPE2DR25D7058-SPE2DR26F8DNS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,558.40 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 25, 2025, with completion by November 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $15,558.30 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 24, 2025, with completion scheduled for September 25, 2025. This firm fixed price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $10,969.97 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order was placed under no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a $26,622.47 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on September 23, 2025, with an ultimate completion date of September 24, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $12,296.10 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on December 15, 2025, with an ultimate completion date of December 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a delivery order valued at $10,437.46 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count bottles) on December 1, 2025, with an ultimate completion date of December 2, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $12,938.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units). This firm fixed price, non-set-aside delivery order was awarded on December 16, 2025, with an ultimate completion date of December 17, 2025. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $21,617.41 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $20,525.18 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on November 26, 2025, with an ultimate completion date of November 28, 2025. This non-set-aside, firm fixed-price delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions,...
- The Defense Logistics Agency awarded a $29,485.37 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency's...
- SPE2DR25D7058Indefinite Delivery Contract
- SPE2DR25D7058-SPE2DR26F8DNSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $13,116.84 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) with a firm fixed price structure. This non-set-aside, competitively awarded contract was executed on December 19, 2025, with an ultimate completion date of December 22, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency Medical Supply Chain's continued procurement of specialized pharmaceutical therapies to support military healthcare systems. This delivery order operates as a child contract under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling value through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and has demonstrated consistent capability to fulfill competitive federal procurement requirements across diverse therapeutic domains, including specialty medications, vaccines, and medical supplies for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.1k | 12/18/25 |